Computational design and biological testing of highly cytotoxic colchicine ring a modifications

Chemical Biology and Drug Design

Volumn 75, Issue 6, 2010, Pages 541-550

  Torin Huzil, John ^a   Winter, Philip ^a   Johnson, Lorelei ^a   Weis, Alexander L ^b   Bakos, Tamas ^b   Banerjee, Asok ^c   Luduena, Richard F ^c   Damaraju, Sambasivarao ^a   Tuszynski, Jack A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b OncoVista Inc   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Colchicine; Cytotoxicity; Docking; Molecular modeling; Rational drug design

Indexed keywords

BETA TUBULIN; COLCHICINE; COLCHICINE DERIVATIVE; ISOPROTEIN; PACLITAXEL;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; BINDING SITE; CALCULATION; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; IC 50; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLCHICINE; COMPUTER SIMULATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN ISOFORMS; THERMODYNAMICS; TUBULIN; TUBULIN MODULATORS;

EID: 77951973915     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.00970.x     Document Type: Article

References (48)

1. Bai R., Pettit G.R., Hamel E. (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39 : 1941 1949. (Pubitemid 20187330)
2. Schiff P.B., Fant J., Horwitz S.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277 : 665 667. (Pubitemid 9114288)
3. Owellen R.J., Owens A.H.J., Donigian D.W. (1972) The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun 47 : 685 691.
4. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., Goetz M., Lazarides E., Woods C.M. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55 : 2325 2333.
5. Lu Q., Luduena R.F. (1994) In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. J Biol Chem 269 : 2041 2047. (Pubitemid 24978467)
6. Luduena R.F. (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178 : 207 275.
7. Roach M.C., Boucher V.L., Walss C., Ravdin P.M., Luduena R.F. (1998) Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell Motil Cytoskeleton 39 : 273 285. (Pubitemid 28153231)
8. Khan I.A., Luduena R.F. (2003) Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain. Invest New Drugs 21 : 3 13.
9. Banerjee A., Luduena R.F. (1992) Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem 267 : 13335 13339.
10. Schwarz P.M., Luduena R.F. (2002) Interaction of nocodazole with tubulin isotypes. Drug Dev Res 55 : 91 96.
11. Katsetos C.D., Legido A., Perentes E., Mork S.J. (2003) Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 18 : 851 866. (Pubitemid 38088739)
12. Katsetos C.D., Kontogeorgos G., Geddes J.F., Herman M.M., Tsimara-Papastamatiou H., Yu Y., Sakkas L.I., Tsokos M., Patchefsky A.S., Ehya H., Cooper H.S., Provencio J., Spano A.J., Frankfurter A. (2000) Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 124 : 535 544. (Pubitemid 30210985)
13. Scott C.A., Walker C.C., Neal D.A., Harper C.E., Bloodgood R.A., Somers K.D., Mills S.E., Rebhun L.I., Levine P.A. (1990) Beta-tubulin epitope expression in normal and malignant epithelial cells. Arch Otolaryngol Head Neck Surg 116 : 583 589.
14. Ravelli R.B., Gigant B., Curmi P.A., Jourdain I., Lachkar S., Sobel A., Knossow M. (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428 : 198 202. (Pubitemid 38374318)
15. Gigant B., Wang C., Ravelli R.B., Roussi F., Steinmetz M.O., Curmi P.A., Sobel A., Knossow M. (2005) Structural basis for the regulation of tubulin by vinblastine. Nature 435 : 519 522. (Pubitemid 40734250)
16. Nogales E., Wolf S.G., Khan I.A., Luduena R.F., Downing K.H. (1995) Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature 375 : 424 427.
17. Huzil J.T., Luduena R.F., Tuszynski J. (2006) Comparative modelling of human beta-tubulin isotypes and implications for drug binding. Nanotechnology 17 : S90 S100. (Pubitemid 43190484)
18. Laclette J.P., Guerra G., Zetina C. (1980) Inhibition of tubulin polymerization by mebendazole. Biochem Biophys Res Commun 92 : 417 423. (Pubitemid 10098582)
19. Tahir S.K., Kovar P., Rosenberg S.H., Ng S.C. (2000) Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. BioTechniques 29 : 156 160. (Pubitemid 30439429)
20. Russell G.J., Lacey E. (1995) Inhibition of [3H]mebendazole binding to tubulin by structurally diverse microtubule inhibitors which interact at the colchicine binding site. Biochem Mol Biol Int 35 : 1153 1159. (Pubitemid 26174736)
21. Hoebeke J., Van Nijen G., De Brabander M. (1976) Interaction of oncodazole (R 17934), a new antitumoral drug, with rat brain tubulin. Biochem Biophys Res Commun 69 : 319 324.
22. Lindahl E., Hess B., van der Spoel D. (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 7 : 306 317. (Pubitemid 36153547)
23. Brooks B.R., Brooks C.L. 3rd., Mackerell A.D. Jr., Nilsson L., Petrella R.J., Roux B., Won Y. et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30 : 1545 1614.
24. Wu G., Robertson D.H., Brooks C.L., Vieth M. (2003) Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24 : 1549 1562.
25. Dumont R., Brossi A., Chignell C.F., Quinn F.R., Suffness M. (1987) A novel synthesis of colchicide and analogues from thiocolchicine and congeners: reevaluation of colchicide as a potential antitumor agent. J Med Chem 30 : 732 735. (Pubitemid 17065215)
26. Bartusik D., Tomanek B., Lattova E., Perreault H., Tuszynski J., Fallone G. (2009) The efficacy of new colchicine derivatives and viability of the T-Lymphoblastoid cells in three-dimensional culture using 19F MRI and HPLC-UV ex vivo. Bioorg Chem 37 : 193 201.
27. Fellous A., Francon J., Lennon A.M., Nunez J. (1977) Microtubule assembly in vitro. Purification of assembly-promoting factors. Eur J Biochem 78 : 167 174. (Pubitemid 8164734)
28. Banerjee A., Roach M.C., Wall K.A., Lopata M.A., Cleveland D.W., Luduena R.F. (1988) A monoclonal antibody against the type II isotype of beta-tubulin. Preparation of isotypically altered tubulin. J Biol Chem 263 : 3029 3034. (Pubitemid 18062960)
29. Lowe J., Li H., Downing K.H., Nogales E. (2001) Refined structure of alpha beta-tubulin at 3.5 A resolution. J Mol Biol 313 : 1045 1057. (Pubitemid 33081900)
30. Brossi A., Yeh H.J., Chrzanowska M., Wolff J., Hamel E., Lin C.M., Quin F., Suffness M., Silverton J. (1988) Colchicine and its analogues: recent findings. Med Res Rev 8 : 77 94. (Pubitemid 18013841)
31. Sun L., Hamel E., Lin C.M., Hastie S.B., Pyluck A., Lee K.H. (1993) Antitumor agents. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: N-acyl-, N-aroyl-, and N-(substituted benzyl)deacetylthiocolchicines as potent cytotoxic and antimitotic compounds. J Med Chem 36 : 1474 1479. (Pubitemid 23164505)
32. Ferrari A.M., Degliesposti G., Sgobba M., Rastelli G. (2007) Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. Bioorg Med Chem 15 : 7865 7877. (Pubitemid 47575902)
33. Cucchiarelli V., Hiser L., Smith H., Frankfurter A., Spano A., Correia J.J., Lobert S. (2008) Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. Cell Motil Cytoskeleton 65 : 675 685.
34. Kavallaris M., Kuo D.Y., Burkhart C.A., Regl D.L., Norris M.D., Haber M., Horwitz S.B. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100 : 1282 1293. (Pubitemid 27386315)
35. Tommasi S., Mangia A., Lacalamita R., Bellizzi A., Fedele V., Chiriatti A., Thomssen C., Kendzierski N., Latorre A., Lorusso V., Schittulli F., Zito F., Kavallaris M., Paradiso A. (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 120 : 2078 2085. (Pubitemid 46555844)
36. Banerjee A. (2002) Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. Biochem Biophys Res Commun 293 : 598 601. (Pubitemid 34694251)
37. Derry W.B., Wilson L., Khan I.A., Luduena R.F., Jordan M.A. (1997) Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36 : 3554 3562. (Pubitemid 27143509)
38. Burgoyne R.D., Cambray-Deakin M.A., Lewis S.A., Sarkar S., Cowan N.J. (1998) Differential distribution of beta-tubulin isotypes in cerebellum. EMBO J 7 : 2311 2319.
39. Ferlini C., Raspaglio G., Mozzetti S., Cicchillitti L., Filippetti F., Gallo D., Fattorusso C., Campiani G., Scambia G. (2005) The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 65 : 2397 2405. (Pubitemid 40490151)
40. Luduena R.F., Prasad V., Roach M.C., Lacey E. (1998) The interaction of phomopsin A with bovine brain tubulin. Arch Biochem Biophys 272 : 32 38. (Pubitemid 24167272)
41. Luduena R.F., Roach M.C., Prasad V., Chaudhuri A.R., Tomita I., Mizuhashi F., Murata K. (1995) Interaction of bovine brain tubulin with the 4(1H)-pyrizinone derivative IKP104, an antimitotic drug with a complex set of effects on the conformational stability of the tubulin molecule. Biochemistry 34 : 15751 15759.
42. Schwarz P.M., Liggins J.R., Luduena R.F. (1998) Beta-tubulin isotypes purified from bovine brain have different relative stabilities. Biochemistry 37 : 4687 4692.
43. Chaudhuri A.R., Tomita I., Mizuhashi F., Murata K., Luduena R.F. (1998) Tubulin stability and decay: mediation by two distinct classes of IKP104-binding sites. J Protein Chem 17 : 303 309. (Pubitemid 28242300)
44. Chaudhuri A.R., Seetharamalu P., Schwarz P.M., Hausheer F.H., Luduena R.F. (2000) The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach. J Mol Biol 303 : 679 692.
45. Carles G., Braguer D., Dumontet C., Bourgarel V., Goncalves A., Sarrazin M., Rognoni J.B., Briand C. (1999) Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 80 : 1162 1168. (Pubitemid 29264075)
46. Dozier J.H., Hiser L., Davis J.A., Thomas N.S., Tucci M.A., Benghuzzi H.A., Frankfurter A., Correia J.J., Lobert S. (2003) Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res 5 : R157 R169.
47. Gan P.P., Pasquier E., Kavallaris M. (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67 : 9356 9363. (Pubitemid 47535925)
48. Ranganathan S., Dexter D.W., Benetatos C.A., Chapman A.E., Tew K.D., Hudes G.R. (1996) Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 56 : 2584 2589. (Pubitemid 26170695)